

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELL-0072 (PA 439.3)	Serial No. 09/326,020
		Applicant John Robert Porter, et al.	
		Filing Date June 4, 1999	Group 1625
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
✓	AA	Alhaique, F., et al., "Cyclisation of dinitriles by sodium alkoxides a new synthesis of naphthyridines," <i>Tetrahedron Letters</i> , 1975 , 3, 173-174	
✓	AB	Ames, D.E., et al., "Condensation of β -dicarbonyl compounds with halogenopyridinecarb-oxylic acids. A convenient synthesis of some naphthyridine derivatives," <i>J.C.S. Perkin I</i> , 1972 , 705-710	
✓	AC	Bodor, N., "Novel approaches in prodrug design," <i>Alfred Benzon Symposium</i> , 1982 , 17, 156-177	
✓	AD	Brooks, Peter C., et al., "Antiintegrin $\alpha\beta 3$ blocks human breast cancer growth and angiogenesis in human skin," <i>J. Clin. Invest.</i> , 1995 , 96, 1815-1822	
*	AE	Bundgaard, H., <i>Design of Prodrugs</i> , 1985 , Elsevier, Amsterdam	
*	AF	Katritzky, A.R., et al. (Eds.), <i>Comprehensive Organic Functional Group Transformations</i> , Pergamon, 1995	
✓	AG	Davies, S.G., et al., "Asymmetric synthesis of R- β -amino butanoic acid and S- β -tyrosine: homochiral lithium amide equivalents for Michael additions to α,β -unsaturated esters," <i>Tetra. Asymmetry</i> , 1991 , 2(3), 183-186	
✓	AH	Erle, D.J., et al., "Expression and function of the MadCAM-1 receptor, integrin $\alpha 4 \beta 7$, on human leukocytes," <i>J. Immunol.</i> , 1994 , 153, 517-528	
*	AI	Encyclopedia of Reagents for Organic Synthesis, <i>John Wiley and Sons (eds.)</i> , 1995	
✓	AJ	Giacomello, et al., "Synthesis of 2,6-naphthyridine," <i>Tetra. Letters</i> , 1965 , 16, 1117-1121	
EXAMINER		DATE CONSIDERED	

* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and easily obtainable by the Examiner.

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELL-0072 (PA 439.3)	Serial No. 09/326,020
		Applicant John Robert Porter, et al.	
		Filing Date June 4, 1999	Group 1625
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
*	AK	Green, T.W., et al., "Protective Groups in Organic Synthesis," <i>John Wiley and Sons (eds.)</i> , 1991	
✓	AL	Hammes, H., et al., "Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization," <i>Nature Medicine</i> , 1996, 2, 529-533	
✓	AM	Hodivala-Dilke, K.M., "β3-integrin-deficient mice are a model for glanzmann thrombasthenia showing placental defects and reduced survival," <i>J. Clin. Invest.</i> , 1999, 103(2), 229-238	
✓	AN	Kalvin, D.M., et al., Synthesis of (4R)-D,L-[4- ² H]- and (4S)-D,L-[4- ² H] homoserine lactones," <i>J. Org. Chem.</i> , 1985, 50, 2259-2263	
✓	AO	Koivunen, E., et al., "Selection of peptides binding to the α ₅ β ₁ integrin from phage display library," <i>J. Biological Chemistry</i> , 1993, 268(27), 20205-20210	
✓	AP	Mitjans, F., et al., "An anti-αv-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice," <i>J. Cell Science</i> , 1995, 108, 2825-2838	
✓	AQ	Molina, P., et al., "Iminophosphorane-mediated annelation of a pyridine ring into a preformed pyridine one: synthesis of naphthyridine, pyrido [1,2-c] pyrimidine and pyrido [1,2-c] quinazoline derivatives," <i>Tetrahedron</i> , 1992, 48(22), 4601-4616	
✓	AR	Newham, P., et al., "Integrin adhesion receptors: structure, function and implications for biomedicine," <i>Molecular Medicine Today</i> , 1996, 304-313	
✓	AS	Numata, A., et al., "General synthetic method for naphthyridines and their N-oxides containing isoquinolinic nitrogen," <i>Synthesis</i> , 1999, 2, 306-311	
✓	AT	Sakamoto, T., et al., "Condensed heteroaromatic ring systems. III. synthesis of naphthyridine derivatives by cyclization of ethynylpyridinecarboxamides," <i>Chem. Pharm. Bull.</i> 1985, 33(2), 626-633	
EXAMINER		DATE CONSIDERED	

* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner.

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELL-0072 (PA 439.3)	Serial No. 09/326,020
		Applicant John Robert Porter, et al.	
		Filing Date June 4, 1999	Group 1625
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
✓	AU	Singh, G., et al., "Prodrug approach in new drug design and development," <i>J. Sci. Ind. Res.</i> , 1996 , <i>55</i> , 497-510	
✓	AV	Srivatsa, S.S., et al., "Selective $\alpha\text{v}\beta 3$ integrin blockade potentially limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: evidence for the functional importance of integrin $\alpha\text{v}\beta 3$ and osteopontin expression during neointima formation," <i>Cardiovascular Research</i> , 1997 , <i>36</i> , 408-428	
✓	AW	Stupack, D.G., et al., "induction of $\alpha\text{v}\beta 3$ integrin-mediated attachment to extracellular matrix in β_1 integrin (CD29)-negative B cell lines," <i>Experi. Cell Research</i> , 1992 , <i>203</i> , 443-448	
✓	AX	Tan R., et al., "Synthesis of 2, 6-naphthyridine and some of its derivatives," <i>Tetrahedron Letters</i> , 1965 , <i>31</i> , 2737-2744	
EXAMINER		DATE CONSIDERED	